These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19228421)

  • 1. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.
    Pascual-Ramos V; Contreras-Yáñez I; Villa AR; Cabiedes J; Rull-Gabayet M
    Arthritis Res Ther; 2009; 11(1):R26. PubMed ID: 19228421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters.
    Contreras-Yáñez I; Pascual-Ramos V
    Arthritis Res Ther; 2015 Jul; 17(1):177. PubMed ID: 26162892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence on therapy is a major determinant of patient-, physician- and laboratory- reported outcomes in recent-onset rheumatoid arthritis patients.
    Contreras-Yáñez I; Cabiedes J; Villa AR; Rull-Gabayet M; Pascual-Ramos V
    Clin Exp Rheumatol; 2010; 28(5):748-51. PubMed ID: 20863447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
    Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
    Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.
    Pan Y; Norton S; Gwinnutt JM; Kearsley-Fleet L; Symmons DPM; Lunt M; Young A; ; Hyrich KL; Verstappen SMM
    PLoS One; 2019; 14(5):e0215999. PubMed ID: 31107887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
    Welsing PM; Fransen J; van Riel PL
    Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
    Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
    Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
    Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
    J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In early arthritis patients, high HAQ at baseline and DAS28 at three months predict suboptimal outcomes at two years: a retrospective cohort study.
    Fanouriakis A; Papalopoulos I; Gergianaki I; Spyrou G; Erden A; Rapsomaniki P; Terizaki M; Avgoustidis N; Repa A; Kougkas N; Bertsias G; Boumpas DT; Sidiropoulos PI
    Clin Exp Rheumatol; 2018; 36(5):806-813. PubMed ID: 29533750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients: patient-reported outcomes from multiple controlled and open-label extension studies.
    Schiff MH; Yu EB; Weinblatt ME; Moreland LW; Genovese MC; White B; Singh A; Chon Y; Woolley JM
    Drugs Aging; 2006; 23(2):167-78. PubMed ID: 16536638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort.
    Gamboa-Cárdenas RV; Ugarte-Gil MF; Loreto M; Sacnun MP; Saurit V; Cardiel MH; Soriano ER; Pisoni C; Galarza-Maldonado CM; Rios C; Radominski SC; Castelar-Pinheiro GDR; Bianchi WA; Appenzeller S; da Silveira IG; de Freitas Zerbini CA; Caballero-Uribe CV; Rojas-Villarraga A; Guibert-Toledano M; Ballesteros F; Montufar R; Vázquez-Mellado J; Esquivel-Valerio J; De La Torre IG; Barile-Fabris LA; Palezuelos FI; Andrade-Ortega L; Monge P; Teijeiro R; Achurra-Castillo ÁF; Esteva Spinetti MH; Alarcón GS; Pons-Estel BA
    Clin Rheumatol; 2019 Oct; 38(10):2737-2746. PubMed ID: 31161486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
    Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
    Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register.
    Twigg S; Hensor EMA; Emery P; Tennant A; Morgan AW;
    J Rheumatol; 2017 Sep; 44(9):1331-1340. PubMed ID: 28668806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age at onset determines severity and choice of treatment in early rheumatoid arthritis: a prospective study.
    Innala L; Berglin E; Möller B; Ljung L; Smedby T; Södergren A; Magnusson S; Rantapää-Dahlqvist S; Wållberg-Jonsson S
    Arthritis Res Ther; 2014 Apr; 16(2):R94. PubMed ID: 24731866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.
    Aletaha D; Maa JF; Chen S; Park SH; Nicholls D; Florentinus S; Furtner D; Smolen JS
    Ann Rheum Dis; 2019 Dec; 78(12):1609-1615. PubMed ID: 31434637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of medication adherence on disease activity among Japanese patients with rheumatoid arthritis.
    Nakagawa S; Nakaishi M; Hashimoto M; Ito H; Yamamoto W; Nakashima R; Tanaka M; Fujii T; Omura T; Imai S; Nakagawa T; Yonezawa A; Imai H; Mimori T; Matsubara K
    PLoS One; 2018; 13(11):e0206943. PubMed ID: 30388179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do radiographic joint damage and disease activity influence functional disability through different mechanisms? Direct and indirect effects of disease activity in established rheumatoid arthritis.
    Nair SC; Bijlsma JW; van der Werf JH; van der Veen MJ; Linn-Rasker SP; Vreugdenhil S; Lafeber FP; Welsing PM
    J Rheumatol; 2013 Sep; 40(9):1505-12. PubMed ID: 23818710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry.
    Shadick NA; Gerlanc NM; Frits ML; Stolshek BS; Brady BL; Iannaccone C; Collier D; Cui J; Mutebi A; Weinblatt ME
    Clin Rheumatol; 2019 Nov; 38(11):3081-3092. PubMed ID: 31353421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.